Welcome to today's MNT newsletter, containing the most recent headlines from your chosen news categories.
----------------------------------------------------------------------------------- ANNOUNCEMENT
Following reader feedback, we will be testing multiple email formats over the coming weeks. Thank you for your continued support. ----------------------------------------------------------------------------------- |
Alcohol / Addiction / Illegal Drugs News | How the body processes alcohol How long does it takes for the body to process alcohol? Learn about the risks of drinking long-term, and what factors affect the speed it is processed. | 06 Nov 2017 |
Dermatology News | Vitamin D may improve wound healing in burns patients New research finds that burns patients with severe wounds recover better if they have high levels of vitamin D, which is known to fight infection. | 06 Nov 2017 | What is a heliotrope rash? A heliotrope rash may appear as a purple rash on or around the eyelids. Learn more about the causes and risk factors of this rash. | 06 Nov 2017 |
Prostate / Prostate Cancer News | Men with low testosterone less likely to have prostate cancer New study findings confirm the so-called androgen receptor saturation theory and may help to reduce prostate cancer risk in the future. | 06 Nov 2017 | Warfarin may prevent cancer The anticoagulant warfarin may do more than prevent blood clots. Researchers have found that the drug may also protect against cancer development. | 06 Nov 2017 | Are there any alternatives to Flomax? BPH is a condition often treated with a drug called Flomax. A number of alternatives can help people with BPH relieve their symptoms and feel better. | 06 Nov 2017 |
You are receiving this newsletter because you subscribed through your MNT account on Medical News Today. If you wish to alter any of your subscription details (name, email address etc) or chosen news categories, please log into your newsletter preferences page.
To unsubscribe from these newsletters immediately, please click here. | |
No comments:
Post a Comment